Speaking today at the 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) Jagbir Gill, MD, Associate Professor of Medicine in the Division… read more.
Kidney stones can cause some of the most intense pain people ever experience, affecting daily life and leading many to hospital emergency visits. It affects 1 in 11… read more.
People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and… read more.
Hansa Biopharma AB announced that the FDA has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User… read more.
The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney… read more.
Hansa Biopharma AB announced that its Biologics License Application (BLA) for imlifidase has been accepted by the FDA. The FDA’s filing review was completed on day 60 which… read more.
Researchers from the University of Nottingham have uncovered a surprising biological quirk in domestic cats that may help explain why they are so prone to chronic kidney disease…. read more.
NICE (UK): Avelumab plus axitinib can be used as an option for untreated advanced renal cell carcinoma (RCC) in adults, only if: i) they have a favourable-risk status,… read more.
Eating a plant-forward diet and limiting added sugars and fats as part of the EAT–Lancet planetary diet was associated with a reduced risk of chronic kidney disease (CKD),… read more.
Idorsia Ltd announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium taking place from February 2-6, 2026…. read more.
Subtle abnormalities in kidney function – even within the range considered normal – may help identify people at risk of developing chronic kidney disease. This is shown in… read more.
Sobi announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
